Update on pharmaceutical waste disposal regulations: Strategies for success

Brechtelsbauer, Erich; Shah, Shailly

doi:10.1093/ajhp/zxz360

Cited by 16 publications

(8 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[25][26] that include the Centers for Disease Control and Prevention (CDC) of the United States of America, the Saudi Center for Diseases Control (SCDC), the World Health Organization (WHO), the American Society of Health-System Pharmacist (ASHP), and the United States Pharmacopeia (USP). [5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] The committee of pharmacy infection control contains various members, including clinical pharmacists, community pharmacists, and infection control specialists. The first author drafted the policy guidelines, and the second author reviewed and corrected them.…”

Section: Methodsmentioning

confidence: 99%

“…Waste management in pharmacy facilities [13][14][15][16][17][18][19][20] The infection control pharmacist suggested following this policy and procedures for pharmacy management wastages, as explored in Figure 2. 1.…”

Section: Spill Control Of Hazardous Drugsmentioning

confidence: 99%

“…[7][8][9][10][11][12] Other literature discussed pharmacy wastage and spill kit management. [5][6][13][14][15][16][17][18][19][20] Additional investigations revealed varying levels of compliance with wastage material disposal by the healthcare professionals. [21][22][23][24] However, few publications on pharmacy policy regarding wastage and spillage of critical materials were found during the literature review.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Pharmacy Infection Control: Wastages and Spill Cleaning

Alomi¹,

Alyousef²,

Islam³

et al. 2022

PTB Reports

View full text Add to dashboard Cite

Objective: In this study, we aimed to illustrate pharmacy infection control wastages and spill cleaning policy as a new initiative in Saudi Arabia. Methods: This narrative review of pharmacy infection control emphasizes wastages and spill cleaning. A literature search was done using various databases containing PubMed, Medline, and Google Scholar. About specific pharmacy practice infection control policies and procedures. The search time was from the 1960s to October 2021. The topic was English, including narrative review, systemic review, meta-analysis, and guidelines across hospitals and community pharmacy services. Moreover, the national and international guidelines of general research in hospital practice. The committee of pharmacy research formulated and consisted of various experts, including clinical pharmacists, drug information pharmacists, and infection control specialists. The first author drafted the policy guidelines, and the second author reviewed and corrected them. The third author, an infection control specialist, revised the final document. The study emphasizes policy and procedures related to wastage and spill cleaning for pharmacy infection control. Results: The wastages and spill cleaning policy of pharmacy infection control consisted of various items, including the types of pharmacy wastages (biohazard wastages, non-biohazard wastages, sharp material), steps in the management of pharmacy wastages, spill kit contents, and cleaning of spill material. Conclusion: The policy and procedures of wastages and spill cleaning are new initiative procedures aimed at pharmacy infection control. In pharmacy settings, it is part of the biohazard and safety foundation. As such, waste management and spill clean-up policies are critical in pharmaceutical care services to improve safe disposal.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Spill Control Of Hazardous Drugsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pharmacy Infection Control: Wastages and Spill Cleaning

Alomi¹,

Alyousef²,

Islam³

et al. 2022

PTB Reports

View full text Add to dashboard Cite

show abstract

“…In some regions, mixing waste streams is standard practice. The US Food and Drug Administration (FDA) website includes recommendations for disposing of medicines at home, including flushing down the toilet or placing in a container and adding to general household waste [ 3 ], despite this practice being discouraged by the Environmental Protection Agency (EPA) [ 4 ]. In New Zealand, people are encouraged to return their unwanted medicines to their pharmacy for safe disposal and all pharmacies offer a free-to-consumer collection and disposal service for unwanted medicines [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Quantification and composition of pharmaceutical waste in New Zealand

Hanning

Hua

Baroutian

et al. 2022

J Mater Cycles Waste Manag

View full text Add to dashboard Cite

This study aimed to quantify the amount of pharmaceutical waste produced in New Zealand, and determine the composition of pharmaceutical waste from community pharmacies in Auckland, New Zealand. Pharmaceutical waste collected in New Zealand is increasing, peaking at 542 tonne in 2019. Pharmaceutical waste collected from hospitals and pharmacies in Auckland increased by more than fourfold from 2016 to 2020. An audit of the types of pharmaceutical waste collected from community pharmacies revealed that the most common classes of drugs identified in this waste stream belonged to the nervous system, cardiovascular system and alimentary tract, and metabolism. Following examination of the contents of 12 pharmaceutical waste bins, 475 different pharmaceutical products were identified, highlighting the breadth of drugs in this waste stream. A range of dosage forms and hence materials were identified, which could present challenges for future waste treatment approaches. Hazardous drugs were identified including cytotoxic compounds, which should go into a separate waste stream for incineration. There is a need for similar data to be collected from multiple sites to fully appreciate the magnitude and composition of pharmaceutical waste. This will allow for the suitability of current practices for managing this hazardous waste stream to be evaluated.

show abstract

“…Therefore, there tends to either be a shortage or an excess of each desired drug with current centralized manufacturing processes. When there is excess drug product that cannot be used before its expiration, it must be disposed of properly or risk contaminating water supplies (7) , which adds an additional cost burden. Taken together, the current approach for biomanufacturing peptide and protein therapeutics can limit response time, distribution of medicines, and drive healthcare inequities.…”

Section: Introductionmentioning

confidence: 99%

Point-of-care peptide hormone production enabled by cell-free protein synthesis

DeWinter

Thames

Guerrero

et al. 2022

Preprint

View full text Add to dashboard Cite

In resource-limited settings, it can be difficult to safely deliver sensitive biologic medicines to patients due to cold chain and infrastructure constraints. Point-of-care drug manufacturing could circumvent these challenges because medicines could be produced locally and used on-demand. Towards this vision, we combine cell-free protein synthesis (CFPS) and a 2-in-1 affinity purification and enzymatic cleavage scheme to develop a platform for point-of-care drug manufacturing. As a model, we use this platform to synthesize a panel of peptide hormones, an important class of medications that can be used to treat a wide variety of diseases including diabetes, osteoporosis, and growth disorders. With this approach, temperature-stable lyophilized CFPS reaction components can be rehydrated with DNA encoding a SUMOylated peptide hormone of interest when needed. Strep-Tactin® affinity purification and on-bead SUMO protease cleavage yields peptide hormones in their native form that are recognized by ELISA antibodies and that can bind their respective receptors. With further development to ensure proper biologic activity and patient safety, we envision this platform could be used to manufacture valuable peptide hormone drugs at the point-of-care in resource-limited settings.

show abstract

Update on pharmaceutical waste disposal regulations: Strategies for success

Cited by 16 publications

References 1 publication

Pharmacy Infection Control: Wastages and Spill Cleaning

Pharmacy Infection Control: Wastages and Spill Cleaning

Quantification and composition of pharmaceutical waste in New Zealand

Point-of-care peptide hormone production enabled by cell-free protein synthesis

Contact Info

Product

Resources

About